Among participants with cerebrovascular disease, there was lower risk for all-cause mortality in the GLP-1 receptor group than in the DDP-4 inhibitor group (HR, 0.33; 95% CI, 0.12-0.86). Here, GLP1R is linked to cerebrovascular disorder.